{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:17:49Z","timestamp":1769505469188,"version":"3.49.0"},"reference-count":75,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>Since the onset of the coronavirus disease 2019 pandemic, immune modulators have been considered front-line candidates for the management of patients presenting with clinical symptoms secondary to severe acute respiratory syndrome coronavirus 2 infection. Although heavy emphasis has been placed on early clinical efficacy, we sought to evaluate the impact of pharmacologic approach to coronavirus disease 2019 within the ICU on secondary infections and clinical outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DATA SOURCES:<\/jats:title>\n            <jats:p>PubMed (inception to March 2021) database search and manual selection of bibliographies from selected articles.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>STUDY SELECTION AND DATA EXTRACTION:<\/jats:title>\n            <jats:p>Articles relevant to coronavirus disease 2019, management of severe acute respiratory syndrome coronavirus 2\u2013associated respiratory failure, and prevalence of secondary infections with pharmacotherapies were selected. The MeSH terms \u201cCOVID-19,\u201d \u201csecondary infection,\u201d \u201cSARS-CoV-2,\u201d \u201ctocilizumab,\u201d and \u201ccorticosteroids\u201d were used for article identification. Articles were narratively synthesized for this review.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DATA SYNTHESIS:<\/jats:title>\n            <jats:p>Current data surrounding the use of tocilizumab and\/or corticosteroids for coronavirus disease 2019 management are limited given the short follow-up period and conflicting results between studies. Further complicating the understanding of immune modulator role is the lack of definitive understanding of clinical impact of the immune response in coronavirus disease 2019.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>Based on the current available literature, we suggest prolonged trials and follow-up intervals for those patients managed with immune modulating agents for the management of coronavirus disease 2019.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cce.0000000000000492","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T20:02:51Z","timestamp":1626206571000},"page":"e0492","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacotherapy in Coronavirus Disease 2019 and Risk of Secondary Infections: A Single-Center Case Series and Narrative Review"],"prefix":"10.1097","volume":"3","author":[{"given":"Michael","family":"Behal","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, University of Kentucky, College of Pharmacy, Lexington, KY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brooke","family":"Barlow","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Kentucky, College of Pharmacy, Lexington, KY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Breanne","family":"Mefford","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Kentucky, College of Pharmacy, Lexington, KY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa L.","family":"Thompson Bastin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Kentucky, College of Pharmacy, Lexington, KY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Chris","family":"Donaldson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Kentucky, College of Pharmacy, Lexington, KY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Laine","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Kentucky, College of Pharmacy, Lexington, KY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany D.","family":"Bissell","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Kentucky, College of Pharmacy, Lexington, KY."},{"name":"Department of Pulmonary, Critical Care, and Sleep Medicine, University of Kentucky, College of Medicine, Lexington, KY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,7,13]]},"reference":[{"key":"R1-20240807","first-page":"1757","article-title":"Mild or moderate COVID-19.","volume":"18","author":"Solomon","year":"2020","journal-title":"N Engl J Med"},{"key":"R2-20240807","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with Covid-19.","volume":"384","author":"Gordon","year":"2021","journal-title":"N Engl J Med"},{"key":"R3-20240807","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe Covid-19 pneumonia.","volume":"384","author":"Rosas","year":"2021","journal-title":"N Engl J Med"},{"key":"R4-20240807","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin.","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"R5-20240807","article-title":"Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2.","author":"Zhao","journal-title":"bioRxiv"},{"key":"R6-20240807","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2.","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"R7-20240807","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"R8-20240807","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1172\/JCI126363","article-title":"IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes.","volume":"129","author":"Channappanavar","year":"2019","journal-title":"J Clin Invest"},{"key":"R9-20240807","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.4049\/jimmunol.182.2.1099","article-title":"Type I IFN-mediated protection of macrophages and dendritic cells secures control of murine coronavirus infection.","volume":"182","author":"Cervantes-Barrag\u00e1n","year":"2009","journal-title":"J Immunol"},{"key":"R10-20240807","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","article-title":"Interferon-stimulated genes: A complex web of host defenses.","volume":"32","author":"Schneider","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"R12-20240807","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri3806","article-title":"Regulation of antiviral T cell responses by type I interferons.","volume":"15","author":"Crouse","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"R13-20240807","doi-asserted-by":"crossref","first-page":"5656","DOI":"10.1128\/JVI.00211-10","article-title":"Murine coronavirus delays expression of a subset of interferon-stimulated genes.","volume":"84","author":"Rose","year":"2010","journal-title":"J Virol"},{"key":"R14-20240807","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.chom.2012.04.011","article-title":"Antagonism of the interferon-induced OAS-RNase L pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology.","volume":"11","author":"Zhao","year":"2012","journal-title":"Cell Host Microbe"},{"key":"R15-20240807","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.coviro.2012.04.004","article-title":"SARS coronavirus pathogenesis: Host innate immune responses and viral antagonism of interferon.","volume":"2","author":"Totura","year":"2012","journal-title":"Curr Opin Virol"},{"key":"R16-20240807","article-title":"Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV.","author":"Lokugamage","journal-title":"bioRxiv"},{"key":"R17-20240807","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1164\/rccm.202003-0572LE","article-title":"SARS-CoV-2 viral load in clinical samples from critically ill patients.","volume":"201","author":"Huang","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"R18-20240807","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.mib.2016.11.003","article-title":"Viral-bacterial co-infections in the respiratory tract.","volume":"35","author":"Bakaletz","year":"2017","journal-title":"Curr Opin Microbiol"},{"key":"R19-20240807","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1128\/CMR.00014-10","article-title":"The airway epithelium: Soldier in the fight against respiratory viruses.","volume":"24","author":"Vareille","year":"2011","journal-title":"Clin Microbiol Rev"},{"key":"R20-20240807","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1128\/JVI.80.4.1629-1636.2006","article-title":"Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species- and cell type-dependent manner.","volume":"80","author":"Avadhanula","year":"2006","journal-title":"J Virol"},{"key":"R21-20240807","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.3389\/fimmu.2018.02640","article-title":"Respiratory viral infection-induced microbiome alterations and secondary bacterial pneumonia.","volume":"9","author":"Hanada","year":"2018","journal-title":"Front Immunol"},{"key":"R22-20240807","first-page":"3207","article-title":"\u201cNovel\u201d triggers of herpesvirus reactivation and their potential health relevance.","volume":"1","author":"Dewals","year":"2019","journal-title":"Front Microbiol"},{"key":"R23-20240807","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cmi.2020.07.041","article-title":"Incidence of co-infections and superinfections in hospitalized patients with COVID-19: A retrospective cohort study.","volume":"27","author":"Garcia-Vidal","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"R24-20240807","doi-asserted-by":"crossref","first-page":"e13319","DOI":"10.1111\/eci.13319","article-title":"Bloodstream infections in critically ill patients with COVID-19.","volume":"50","author":"Giacobbe","year":"2020","journal-title":"Eur J Clin Invest"},{"key":"R25-20240807","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jinf.2020.05.046","article-title":"Co-infections in people with COVID-19: A systematic review and meta-analysis.","volume":"81","author":"Lansbury","year":"2020","journal-title":"J Infect"},{"key":"R26-20240807","first-page":"ciaa449","article-title":"Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients.","volume":"6","author":"Chen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R27-20240807","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13613-020-00775-4","article-title":"Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: A retrospective cohort study.","volume":"10","author":"Luyt","year":"2020","journal-title":"Ann Intensive Care"},{"key":"R28-20240807","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1186\/s13054-020-03417-0","article-title":"Risks of ventilator-associated pneumonia and invasive pulmonary aspergillosis in patients with viral acute respiratory distress syndrome related or not to Coronavirus 19 disease.","volume":"24","author":"Razazi","year":"2020","journal-title":"Crit Care"},{"key":"R29-20240807","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.cmi.2020.06.025","article-title":"Bacterial and fungal coinfection among hospitalized patients with COVID-19: A retrospective cohort study in a UK secondary-care setting.","volume":"26","author":"Hughes","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"R30-20240807","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","article-title":"Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: A retrospective cohort study.","volume":"6","author":"Schauwvlieghe","year":"2018","journal-title":"Lancet Respir Med"},{"key":"R31-20240807","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/jof6020091","article-title":"COVID-19 associated pulmonary aspergillosis (CAPA)\u2014from immunology to treatment.","volume":"6","author":"Arastehfar","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"R32-20240807","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1164\/rccm.202004-1038LE","article-title":"COVID-19-associated pulmonary aspergillosis.","volume":"202","author":"van Arkel","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"R33-20240807","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/myc.13096","article-title":"COVID-19 associated pulmonary aspergillosis.","volume":"63","author":"Koehler","year":"2020","journal-title":"Mycoses"},{"key":"R34-20240807","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1164\/rccm.202009-3400OC","article-title":"Occurrence of invasive pulmonary fungal infections in severe COVID-19 patients admitted to the ICU.","volume":"203","author":"Fekkar","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"R35-20240807","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.riam.2020.07.001","article-title":"Revista Iberoamericana de Micolog\u00eda fungal co-infection in COVID-19 patients: Should we be concerned?","volume":"37","author":"Pem\u00e1n","year":"2020","journal-title":"Rev Iberoam Micol"},{"key":"R36-20240807","article-title":"A national strategy to diagnose coronavirus disease 2019\u2013associated invasive fungal disease in the intensive care unit.","author":"White","year":"2020:ciaa1298","journal-title":"Clin Infect Dis"},{"key":"R37-20240807","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200609-1322OC","article-title":"Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation.","volume":"175","author":"Luyt","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"R38-20240807","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jcrc.2015.11.019","article-title":"Herpes simplex virus in bronchoalveolar lavage fluid of medical intensive care unit patients: Association with lung injury and outcome.","volume":"32","author":"Saugel","year":"2016","journal-title":"J Crit Care"},{"key":"R39-20240807","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1186\/s13054-020-03252-3","article-title":"Herpes simplex virus and cytomegalovirus reactivations among severe COVID-19 patients.","volume":"24","author":"Le Balc\u2019h","year":"2020","journal-title":"Crit Care"},{"key":"R41-20240807","doi-asserted-by":"crossref","first-page":"106103","DOI":"10.1016\/j.ijantimicag.2020.106103","article-title":"Tocilizumab for severe COVID-19: A systematic review and meta-analysis.","volume":"56","author":"Lan","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"R42-20240807","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/jmv.26509","article-title":"Efficacy of tocilizumab in COVID-19: A systematic review and meta-analysis.","volume":"93","author":"Aziz","year":"2021","journal-title":"J Med Virol"},{"key":"R43-20240807","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.","volume":"383","author":"Stone","year":"2020","journal-title":"N Engl J Med"},{"key":"R44-20240807","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with covid-19 pneumonia.","volume":"384","author":"Salama","year":"2021","journal-title":"N Engl J Med"},{"key":"R45-20240807","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.semarthrit.2019.01.003","article-title":"Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice.","volume":"49","author":"Calder\u00f3n-Goercke","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"R46-20240807","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3899\/jrheum.141210","article-title":"Longterm safety of tocilizumab: Results from 3 years of followup postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan.","volume":"42","author":"Yamamoto","year":"2015","journal-title":"J Rheumatol"},{"key":"R47-20240807","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/1744666X.2019.1705785","article-title":"Infection risk in patients undergoing treatment for inflammatory arthritis: Non-biologics versus biologics.","volume":"16","author":"Chiu","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"R48-20240807","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights.","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"R49-20240807","doi-asserted-by":"crossref","first-page":"E680","DOI":"10.1503\/cmaj.190178","article-title":"Incidence of infections associated with oral glucocorticoid dose in people diagnosed with polymyalgia rheumatica or giant cell arteritis: A cohort study in England.","volume":"191","author":"Wu","year":"2019","journal-title":"CMAJ"},{"key":"R50-20240807","doi-asserted-by":"crossref","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: Population based cohort study.","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"key":"R51-20240807","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/archsurg.141.2.145","article-title":"Corticosteroid use in the intensive care unit: At what cost?","volume":"141","author":"Britt","year":"2006","journal-title":"Arch Surg"},{"key":"R52-20240807","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1056\/NEJM199912163412507","article-title":"Infections in patients with diabetes mellitus.","volume":"341","author":"Joshi","year":"1999","journal-title":"N Engl J Med"},{"key":"R53-20240807","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1056\/NEJMoa022139","article-title":"The epidemiology of sepsis in the United States from 1979 through 2000.","volume":"348","author":"Martin","year":"2003","journal-title":"N Engl J Med"},{"key":"R54-20240807","doi-asserted-by":"crossref","DOI":"10.1097\/CCM.0000000000005088","article-title":"Comparison of circulating immune cells profiles and kinetics between coronavirus disease 2019 and bacterial sepsis.","author":"de Roquetaillade","year":"2021 May 18","journal-title":"Crit Care Med"},{"key":"R55-20240807","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1002\/jmv.25964","article-title":"Tocilizumab for the treatment of severe coronavirus disease 2019.","volume":"92","author":"Alattar","year":"2020","journal-title":"J Med Virol"},{"key":"R56-20240807","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejim.2020.05.021","article-title":"Efficacy and safety of tocilizumab in severe COVID-19 patients: A single-centre retrospective cohort study.","volume":"76","author":"Campochiaro","year":"2020","journal-title":"Eur J Intern Med"},{"key":"R57-20240807","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1186\/s12879-020-05701-4","article-title":"Effects of tocilizumab in COVID-19 patients: A cohort study.","volume":"20","author":"Vu","year":"2020","journal-title":"BMC Infect Dis"},{"key":"R58-20240807","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: A retrospective cohort study.","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"R59-20240807","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1016\/S2665-9913(20)30277-0","article-title":"Tocilizumab among patients with COVID-19 in the intensive care unit: A multicentre observational study.","volume":"2","author":"Biran","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"R60-20240807","doi-asserted-by":"crossref","first-page":"102568","DOI":"10.1016\/j.autrev.2020.102568","article-title":"Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.","volume":"19","author":"Toniati","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R61-20240807","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.jinf.2020.07.008","article-title":"Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.","volume":"81","author":"Rossotti","year":"2020","journal-title":"J Infect"},{"key":"R62-20240807","article-title":"Tocilizumab for treatment of mechanically ventilated patients with COVID-19.","author":"Somers","year":"2020 Jul 11","journal-title":"Clin Infect Dis"},{"key":"R63-20240807","doi-asserted-by":"crossref","first-page":"e0283","DOI":"10.1097\/CCE.0000000000000283","article-title":"A propensity-matched cohort study of tocilizumab in patients with coronavirus disease 2019.","volume":"2","author":"Lewis","year":"2020","journal-title":"Crit Care Explor"},{"key":"R64-20240807","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia.","volume":"181","author":"Hermine","year":"2020;","journal-title":"JAMA Intern Med"},{"key":"R65-20240807","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: A randomized clinical trial.","volume":"181","author":"Salvarani","year":"2021","journal-title":"JAMA Intern Med"},{"key":"R66-20240807","article-title":"Interleukin-6 receptor antagonists in critically ill patients with Covid-19-preliminary report.","author":"Gordon","journal-title":"MedRX"},{"key":"R67-20240807","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3899\/jrheum.130466","article-title":"Effectiveness and safety of tocilizumab: Postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan.","volume":"41","author":"Koike","year":"2014","journal-title":"J Rheumatol"},{"key":"R68-20240807","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/acr.22470","article-title":"Risks of Herpes Zoster in patients with rheumatoid arthritis according to biologic disease modifying therapy.","volume":"67","author":"Yun","year":"2015","journal-title":"Arthritis Care Res"},{"key":"R69-20240807","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials.","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"R70-20240807","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2146\/ajhp070449","article-title":"Tocilizumab: The first interleukin-6-receptor inhibitor.","volume":"65","author":"Sebba","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"R71-20240807","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19 \u2014 preliminary Report.","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"key":"R72-20240807","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.2020.17021","article-title":"Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: The CoDEX randomized clinical trial.","volume":"324","author":"Tomazini","year":"2020","journal-title":"JAMA"},{"key":"R73-20240807","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1001\/jama.2020.16761","article-title":"Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: A randomized clinical trial.","volume":"324","author":"Dequin","year":"2020","journal-title":"JAMA"},{"key":"R74-20240807","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1093\/cid\/ciaa1177","article-title":"Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): A randomized, double-blind, phase IIb, placebo-controlled trial.","volume":"72","author":"Jeronimo","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R75-20240807","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13054-021-03607-4","article-title":"Tailored modulation of the inflammatory balance in COVID - 19 patients admitted to the ICU?\u2014 a viewpoint.","volume":"25","author":"Kuindersma","year":"2021","journal-title":"Crit Care"},{"key":"R77-20240807","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"R78-20240807","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study.","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"}],"container-title":["Critical Care Explorations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000492","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:03:58Z","timestamp":1723075438000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":75,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/cce.0000000000000492","relation":{},"ISSN":["2639-8028"],"issn-type":[{"value":"2639-8028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}